Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report

Published: July 29, 2026 Report Code: GDHCHT760-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033.

Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting for 55.6% of the market. The 5EU accounted for 41.4% of the global DME market with an estimated value of $1.83 billion, and Japan’s DME market accounted for 2.8% of the market, with an estimated value of $127.5 million in 2024.

Major drivers of DME market growth over the forecast period are the:
– The launch of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with DME, most notably Roche’s Susvimo and Bayer/Regeneron’s high-dose Eylea
– Optimism from key opinion leaders (KOLs) that these therapies could increase the interval between treatments for DME
– An increase in the number of people with DME
– Drugs with a new mechanism of action and/or new route of administration entering the DME market, particularly Oculis’ dexamethasone acetate, which introduces the topical route of administration to the DME space

Major barriers that will restrict the growth of the DME market during the forecast period are the:
– Products that are due to lose exclusivity within the forecast period and the subsequent biosimilar launches of gold-standard therapies
– The DME market already being crowded with anti-VEGF inhibitor therapies, providing competition for new therapies that employ the same mechanism of action

Scope

Overview of diabetic macular edema, including epidemiology, symptoms, diagnosis, and disease management.

Annualized diabetic macular edema therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic macular edema therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic macular edema treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global diabetic macular edema therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM diabetic macular edema therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM diabetic macular edema therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Regeneron
Pfizer
Bayer
Oculis
Outlook Therapeutics
Eyepoint

1 Executive Summary

1.1 Market overview

1.2 The DME market will grow modestly during the forecast period, reaching sales of $6.18 billion in 2034

1.3 Development of longer-acting therapies for DME

1.4 Drugs with improved efficacy represent an important unmet need for DME

1.5 Less invasive formulations are an unmet need for DME

1.6 Late-stage pipeline therapies are anticipated to drive growth in the DME market

1.7 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of DME in diabetes – 7MM

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of DME by involvement of the eye – 7MM

4.5 Epidemiological forecast for DME (2024–34)

4.5.1 Diagnosed prevalent cases of DME in diabetes

4.5.2 Age-specific diagnosed prevalent cases of DME in diabetes

4.5.3 Sex-specific diagnosed prevalent cases of DME in diabetes

4.5.4 Diagnosed prevalent cases of DME by involvement of the eye

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.1.1 Diagnosis overview

5.1.2 Treatment overview

5.1.3 Pharmacotherapy treatments for DME

5.1.4 Surgical treatment options for DME

5.2 Key opinion leader insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Drug safety and efficacy

7.3 Less invasive formulations

7.4 Longer-acting therapy

7.5 Other mechanisms of action

7.6 Earlier diagnosis of patients

8 R&D Strategies

8.1 Overview

8.1.1 Development of novel targets

8.1.2 Longer-acting drugs

8.2 Clinical trial design

8.2.1 Clinical endpoints for DME

8.2.2 Inclusion and exclusion criteria for DME

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 7MM

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecast methodology

13.4 Primary research – key opinion leaders interviewed for this report

13.4.1 Key opinion leaders

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Senior Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologists

13.6.4 Vice President of Disease Intelligence and Epidemiologists

13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: DME – key metrics in the 7MM

Table 2: Classifications of DME as distinguished via FA

Table 3: Classifications of DME as outlined by the International Council of Ophthalmology

Table 4: Risk factors and comorbidities for DME

Table 5: Treatment guidelines for DME

Table 6: Marketed drugs for DME in the 7MM, 2024

Table 7: Top 10 DME deals by value, 2019-2026

Table 8: DME market – global drivers and barriers, 2024-34

Table 9: Key events impacting sales for DME in the US, 2024–34

Table 10: DME Market – drivers and barriers in the US, 2024–34

Table 11: Key events impacting sales for DME in the 5EU, 2024–34

Table 12: DME Market – drivers and barriers in the 5EU, 2024–34

Table 13: Key events impacting sales for DME in Japan, 2024–34

Table 14: DME market – drivers and barriers in Japan, 2024–34

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global DME sales forecast by country in 2024 and 2034

Figure 2: Analysis of the company portfolio gap in DME during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of DME during the forecast period

Figure 4: Etiology of DME

Figure 5: Pathogenic processes in DME

Figure 6: 7MM, diagnosed prevalence of DME in diabetes (%), both sexes, ages ≥20 years, 2024

Figure 7: 7MM, sources used and not used to forecast the diagnosed prevalent cases of DME in diabetes

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of DME by involvement of the eye

Figure 9: 7MM, diagnosed prevalent cases of DME in diabetes, N, both sexes, ages ≥20 years, 2024

Figure 10: 7MM, diagnosed prevalent cases of DME in diabetes by age, N, both sexes, 2024

Figure 11: 7MM, diagnosed prevalent cases of DME in diabetes by sex, N, ages ≥20 years, 2024

Figure 12: 7MM, diagnosed prevalent cases of DME by involvement of the eye, N, both sexes, ages ≥20 years, 2024

Figure 13: Treatment algorithm for DME

Figure 14: Unmet needs and opportunities in DME

Figure 15: Overview of the development pipeline in DME

Figure 16: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for the treatment of DME in the 7MM during the forecast period

Figure 17: Competitive assessment of recently approved and late-stage pipeline agents that GlobalData expects to be licensed for the treatment of DME during the forecast period

Figure 18: Competitive assessment of the pipeline drugs benchmarked against the standard of care

Figure 19: Analysis of the company portfolio gap in DME during the forecast period

Figure 20: 7MM sales forecast by country for DME in 2024 and 2034

Figure 21: 7MM sales forecast by drug class for DME in 2024 and 2034

Figure 22: Sales forecast by class for DME in the US in 2024 and 2034

Figure 23: Sales forecast by class for DME in the 5EU in 2024 and 2034

Figure 24: Sales forecast by class for DME in Japan in 2024 and 2034

Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Diabetic Macular Edema reports

Pharmaceuticals

New

Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline…

Pharmaceuticals

New

Major Depressive Disorder: Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Global M&A Deals in H1 2026 - Top Themes by…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 in real time.

Access a live Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports